Pharmaceutical Contract Development and Manufacturing Market

Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025

Report Code: PH 7263 Mar, 2021, by marketsandmarkets.com

[196 Pages Report] The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.

Pharmaceutical Contract Development and Manufacturing Market

To know about the assumptions considered for the study, download the pdf brochure

COVID-19 impact on the pharmaceutical contract development and manufacturing market

Due to the Covid-19 pandemic, companies have scaled up R&D and manufacturing efforts to develop and distribute vaccines and drugs against the SARS-CoV-2 virus. Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. To expedite the R&D and manufacturing process, many pharmaceutical and biotechnology companies teamed up with CROs and CDMOs through long-term agreements, partnerships, and collaborations across the globe.

Global the pharmaceutical contract development and manufacturing market Dynamics

Drivers Patent expiry and increasing demand for generic drugs

Generics are cost-effective drugs with therapeutic effectiveness and safety profiles that are similar to their branded counterparts. The increasing pressure on reducing the rising healthcare costs is one of the major factors driving the growth of the generics market. According to the Association for Accessible Medicines, the US healthcare system saved USD 313 billion in 2019 alone. In the same year, Medicare and Medicaid saved USD 96 billion and USD 48.5 billion, respectively. Considering such cost benefits, governments across various countries are promoting the use of generic drugs.

The patent expiry of several drugs is another major factor driving the growth of the generics market. In developing countries such as South Korea, around 62 patents for 158 pharmaceutical products are scheduled to expire in 2021. Although generic erosion because of the patent cliff has resulted in significant revenue and volume losses for the branded drugs industry, patent expiration enables the entry of several cheaper generic counterparts in the market (which will boost the volume of drugs sold). This is a positive indicator of market growth, as generics companies outsource around 80% of their production to CDMOs.

Opportunities: Growing demand for cell and gene therapies

Given the personalized nature of cell and gene therapies, they are highly specific and hold the potential to address unmet medical needs associated with treating several disorders. Their promising therapeutic potential has led many pharmaceutical companies and investors to put in a significant amount of capital towards developing and commercializing these therapies. As of 2018, more than six gene therapy products have been approved in various countries. As of February 2020, nine cell and gene therapies are approved by the US FDA. In 2020, around 362 cell and gene therapies were under clinical development. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development and their complex manufacturing process, increases the demand for facilities that offer manufacturing services for these therapies.

The big pharmaceutical companies segment dominated the pharmaceutical contract development and manufacturing market in 2019.

Based on end users, the pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users. In 2019, big pharmaceutical companies accounted for the largest share of the pharmaceutical contract development and manufacturing market, and this trend is expected to continue during the forecast period. The large share of this end-user segment can be attributed to factors such as the high demand for end-to-end services in big pharmaceutical companies, rising pricing pressure and pipeline challenges in their operations (resulting in a shift toward contract development and manufacturing), and the growing need to streamline execution costs as a result of the patent expiry of blockbuster drugs.

The biologics manufacturing services segment will witness the highest growth during the forecast period.

Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing services segment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.

Pharmaceutical Contract Development and Manufacturing Market  by Region

Europe was the largest regional market for pharmaceutical contract development and manufacturing in 2019.

Geographically, the pharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, Europe accounted for the largest share of the pharmaceutical contract development and manufacturing market, followed by North America and the Asia Pacific. The large share of this regional segment in the global market can primarily be attributed to the large number of clinical trials in the region, huge API production base, advanced manufacturing capabilities, presence of leading pharmaceutical companies, and growth in the generics market.

Key Market Players

Key players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland), and  Ingelheim International GmbH (Germany).

Scope of the report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD Billion)

Segments covered

Service, End User, and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GmbH (Germany), FAMAR Health Care Services (France), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland), Evonik Industries AG (Germany), WuXi AppTec (China), Samsung BioLogics (South Korea), Boehringer Ingelheim International GmbH (Germany), Cambrex Corporation (US), CordenPharma International (Germany), Albany Molecular Research Inc. (AMRI) (US), FUJIFILM Corporation (Japan), Piramal Pharma Solutions (India), Baxter International Inc. (US), Eurofins Scientific (Germany), BioVectra (Canada), Jubilant Life Science (India), NextPharma (UK), and Delpharm (France)

This report categorizes the pharmaceutical contract development and manufacturing market into the following segments and subsegments:

Pharmaceutical Contract Development and Manufacturing Market, by Service

  • Pharmaceutical Manufacturing Services
    • Pharmaceutical API Manufacturing Services
    • Pharmaceutical FDF Manufacturing Services
      • Parenteral/injectable manufacturing services
      • Tablet manufacturing services
      • Capsule manufacturing services
      • Oral liquid manufacturing services
      • Semi-solid manufacturing services
      • Other formulations manufacturing services
  • Drug Development Services
  • Biologics Manufacturing Services
    • Biologics API manufacturing services
    • Biologics FDF manufacturing services

Pharmaceutical Contract Development and Manufacturing Market, by End User

  • Big Pharmaceutical Companies
  • Small & Medium-Sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies
  • Other End Users

Pharmaceutical Contract Development and Manufacturing Market, by Region

  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Switzerland
    • Spain
    • Rest of Europe (RoE)
  • North America
    • US
    • Canada
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East and  Africa

Recent Developments

  • In 2021, Lonza Group (Switzerland) entered into an agreement with Aruvant Science (US) to carry out process development (one-time investigational gene therapy—ARU-1801) for sickle-cell treatment in the US
  • In 2020, Catalent (US) acquired Skeletal Theray Support (Belgium). Under this acquisition, Catalent manufactured clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product
  • In 2020, Recipharm AB (Sweden) acquired Consort Medical (UK) Bespak division dealing with inhalation and other devices

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

 

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 25)
 
   1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH APPROACH
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
           FIGURE 1 BREAKDOWN OF PRIMARIES: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
           2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
           FIGURE 2 DATA TRIANGULATION METHODOLOGY
    2.2 MARKET ESTIMATION METHODOLOGY
           2.2.1 MARKET SIZE ESTIMATION APPROACH
           FIGURE 3 COMPANY REVENUE ANALYSIS-BASED ESTIMATION
           FIGURE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE (USD BILLION): FINAL MARKET SIZE
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
           FIGURE 5 FINAL CAGR PROJECTIONS (2020−2025)
    2.4 INSIGHTS FROM PRIMARIES
           FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 35)
           FIGURE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY SERVICE, 2019
           FIGURE 8 BIOLOGICS MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2019
           FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2020 VS. 2025 (USD BILLION)
           FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

4 PREMIUM INSIGHTS (Page No. - 39)
    4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW
           FIGURE 11 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
    4.2 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
           FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES TO COMMAND THE LARGEST SHARE OF THE EUROPEAN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER
           FIGURE 13 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
    4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES BETWEEN 2020 & 2025

5 MARKET OVERVIEW (Page No. - 43)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
           5.2.1 DRIVERS
                    5.2.1.1 Patent expiry and increasing demand for generic drugs
                    5.2.1.2 Increasing investments in pharmaceutical R&D
           FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020)
           FIGURE 17 GLOBAL R&D SPENDING (2016–2020)
                    5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Increasing demand for biological therapies
                    5.2.2.2 Growth in the nuclear medicine sector
                    5.2.2.3 Growing demand for cell and gene therapies
           5.2.3 CHALLENGES
                    5.2.3.1 Introduction of serialization
           5.2.4 TRENDS
                    5.2.4.1 Expansion in emerging countries
                    5.2.4.2 CDMO industry consolidation
           TABLE 1 LIST OF ACQUISITIONS
    5.3 VALUE CHAIN ANALYSIS
           FIGURE 18 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    5.4 ECOSYSTEM MARKET MAP
           FIGURE 19 ECOSYSTEM OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    5.5 SUPPLY CHAIN
    5.6 IMPACT OF THE COVID-19 PANDEMIC ON THE GROWTH OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
           TABLE 2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
           5.6.1 IMPACT ON THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
           FIGURE 20 PRE-COVID VS. POST-COVID-19 SCENARIO, 2019–2021
    5.7 REGULATORY ASSESSMENT
           5.7.1 INTRODUCTION
    5.8 PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF SUPPLIERS
           5.8.4 BARGAINING POWER OF BUYERS
           5.8.5 DEGREE OF COMPETITION

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE (Page No. - 59)
    6.1 INTRODUCTION
           TABLE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
    6.2 PHARMACEUTICAL MANUFACTURING SERVICES
           TABLE 4 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 5 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
                    6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
           TABLE 6 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
           TABLE 7 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 8 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.1 Parenteral/injectable manufacturing services
                               6.2.2.1.1 Need for high levels of expertise and growing drug development activities are driving the demand for contract manufacturing
           TABLE 9 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.2 Tablet manufacturing services
                               6.2.2.2.1 Shifting manufacturing requirements and the need to streamline production processes are driving market growth
           TABLE 10 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.3 Capsule manufacturing services
                               6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
           TABLE 11 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.4 Oral liquid manufacturing services
                               6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to opt for outsourcing
           TABLE 12 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.5 Semi-solid manufacturing services
                               6.2.2.5.1 Demand for specific manufacturing facilities to boost the outsourcing of semi-solids
           TABLE 13 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.6 Other formulations manufacturing services
           TABLE 14 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.3 DRUG DEVELOPMENT SERVICES
           6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
           TABLE 15 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    6.4 BIOLOGICS MANUFACTURING SERVICES
           TABLE 16 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 17 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           6.4.1 BIOLOGICS API MANUFACTURING SERVICES
                    6.4.1.1 Market for biologics API manufacturing is still in the nascent phase
           TABLE 18 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
                    6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing
           TABLE 19 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER (Page No. - 78)
    7.1 INTRODUCTION
           TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
    7.2 BIG PHARMACEUTICAL COMPANIES
           7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
           TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
    7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
           7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH
           TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
    7.4 GENERIC PHARMACEUTICAL COMPANIES
           7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
           TABLE 23 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
    7.5 OTHER END USERS
           TABLE 24 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION (Page No. - 86)
    8.1 INTRODUCTION
           FIGURE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
           TABLE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2018–2025 (USD MILLION)
    8.2 EUROPE
           FIGURE 22 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
           TABLE 26 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 27 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 28 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 29 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 30 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 31 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.1 GERMANY
                    8.2.1.1 High healthcare expenditure and increased pharmaceutical production to support market growth
           TABLE 32 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 33 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 34 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 35 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 36 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.2 ITALY
                    8.2.2.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
           TABLE 37 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 38 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 39 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 40 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 41 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.3 FRANCE
                    8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
           TABLE 42 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 43 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 44 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 45 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 46 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.4 UK
                    8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
           TABLE 47 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 48 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 49 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 50 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 51 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.5 SWITZERLAND
                    8.2.5.1 Large volume of pharmaceutical production and growing scope for generics to provide growth opportunities
           TABLE 52 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 53 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 54 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 55 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 56 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.6 SPAIN
                    8.2.6.1 Increase in biologics production to support market growth
           TABLE 57 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 58 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 59 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 60 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 61 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.2.7 REST OF EUROPE
           TABLE 62 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 63 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY TYPE, 2018–2025 (USD MILLION)
           TABLE 64 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 65 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 66 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.3 NORTH AMERICA
           TABLE 67 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 68 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 69 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 70 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 71 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 72 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.3.1 US
                    8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market
           TABLE 73 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 74 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 75 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 76 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 77 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.3.2 CANADA
                    8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper the market growth
           TABLE 78 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 79 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 80 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 81 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 82 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.4 ASIA PACIFIC
           FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
           TABLE 83 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 84 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 85 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 86 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 87 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.4.1 CHINA
                    8.4.1.1 Favorable government regulations are fueling market growth in China
           TABLE 89 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 90 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 91 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 92 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 93 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.4.2 INDIA
                    8.4.2.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
           TABLE 94 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 95 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 96 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 97 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 98 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.4.3 SOUTH KOREA
                    8.4.3.1 Government investments are a key contributor to market growth in South Korea
           TABLE 99 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 100 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 101 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           8.4.4 JAPAN
                    8.4.4.1 Growing generics demand and government initiatives to drive the demand for contract manufacturing of drugs
           TABLE 102 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 103 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 104 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 105 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 106 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
           8.4.5 REST OF ASIA PACIFIC
           TABLE 107 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 108 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 109 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 110 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 111 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.5 LATIN AMERICA
           8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
           TABLE 112 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 113 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 114 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 115 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 116 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.6 MIDDLE EAST & AFRICA
           8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR CONTRACT MANUFACTURERS IN THE REGION
           TABLE 117 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION)
           TABLE 118 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 119 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 132)
    9.1 OVERVIEW
    9.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    9.3 MARKET SHARE ANALYSIS
           FIGURE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANK, BY KEY PLAYER, 2019
           TABLE 120 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
    9.4 COMPETITIVE LEADERSHIP MAPPING
           9.4.1 STARS
           9.4.2 EMERGING LEADERS
           9.4.3 PERVASIVE PLAYERS
           9.4.4 PARTICIPANTS
           FIGURE 26 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT (2019)
    9.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2019
           9.5.1 PROGRESSIVE COMPANIES
           9.5.2 STARTING BLOCKS
           9.5.3 RESPONSIVE COMPANIES
           9.5.4 DYNAMIC COMPANIES
           FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: STARTUP/SME EVALUATION MATRIX, 2019
    9.6 COMPANY SERVICE FOOTPRINT
           TABLE 121 SERVICE PORTFOLIO ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    9.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
           TABLE 122 GEOGRAPHIC REVENUE MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019)
    9.8 COMPETITIVE SCENARIO
           TABLE 123 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, MAY 2019–OCTOBER 2020
           TABLE 124 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, MARCH 2019–JANUARY 2021
           TABLE 125 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHERS, MAY 2019–NOVEMBER 2020

10 COMPANY PROFILES (Page No. - 145)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)* 
     10.1 MAJOR PLAYERS
             10.1.1 LONZA GROUP
           TABLE 126 LONZA GROUP: BUSINESS OVERVIEW
           FIGURE 28 LONZA GROUP: COMPANY SNAPSHOT (2020)
           TABLE 127 LONZA GROUP: SERVICES OFFERED
             10.1.2 THERMO FISHER SCIENTIFIC INC.
           TABLE 128 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
           FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
           TABLE 129 THERMO FISHER SCIENTIFIC: SERVICES OFFERED
             10.1.3 CATALENT
           TABLE 130 CATALENT: BUSINESS OVERVIEW
           FIGURE 30 CATALENT: COMPANY SNAPSHOT (2020)
           TABLE 131 CATALENT: SERVICES OFFERED
             10.1.4 RECIPHARM AB
           TABLE 132 RECIPHARM AB: BUSINESS OVERVIEW
           FIGURE 31 RECIPHARM AB: COMPANY SNAPSHOT (2019)
           TABLE 133 RECIPHARM AB: SERVICES OFFERED
             10.1.5 ABBVIE
           TABLE 134 ABBVIE: BUSINESS OVERVIEW
           FIGURE 32 ABBVIE: COMPANY SNAPSHOT (2019)
           TABLE 135 ABBVIE: SERVICES OFFERED
             10.1.6 SIEGFRIED HOLDING AG
           TABLE 136 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
           FIGURE 33 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2019)
           TABLE 137 SIEGFRIED HOLDING AG: SERVICES OFFERED
             10.1.7 EVONIK INDUSTRIES
           TABLE 138 EVONIK INDUSTRIES: BUSINESS OVERVIEW
           FIGURE 34 EVONIK INDUSTRIES: COMPANY SNAPSHOT (2019)
           TABLE 139 EVONIK INDUSTRIES: SERVICES OFFERED
             10.1.8 BOEHRINGER INGELHEIM
           TABLE 140 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
           FIGURE 35 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
           TABLE 141 BOEHRINGER INGELHEIM: SERVICES OFFERED
             10.1.9 PIRAMAL PHARMA SOLUTIONS
           TABLE 142 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
           FIGURE 36 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2019)
           TABLE 143 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED
             10.1.10 SAMSUNG BIOLOGICS
           TABLE 144 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
           FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2019)
           TABLE 145 SAMSUNG BIOLOGICS: SERVICES OFFERED
             10.1.11 WUXI APPTEC (WUXI STA)
           TABLE 146 WUXI APPTEC: BUSINESS OVERVIEW
           FIGURE 38 WUXI APPTEC: COMPANY SNAPSHOT (2019)
           TABLE 147 WUXI APPTEC: SERVICES OFFERED
             10.1.12 FUJIFILM HEALTHCARE
           TABLE 148 FUJIFILM HEALTHCARE: BUSINESS OVERVIEW
           FIGURE 39 FUJIFILM HEALTHCARE: COMPANY SNAPSHOT (2019)
           TABLE 149 FUJIFILM HEALTHCARE: SERVICES OFFERED
     10.2 OTHER PLAYERS
             10.2.1 VETTER PHARMA INTERNATIONAL
           TABLE 150 VETTER PHARMA INTERNATIONAL: BUSINESS OVERVIEW
           TABLE 151 VETTER PHARMA INTERNATIONAL: SERVICES OFFERED
             10.2.2 FAMAR HEALTH CARE SERVICES
           TABLE 152 FAMAR HEALTH CARE SERVICES: BUSINESS OVERVIEW
           TABLE 153 FAMAR HEALTH CARE SERVICES: SERVICES OFFERED
             10.2.3 AENOVA GROUP
           TABLE 154 AENOVA GROUP: BUSINESS OVERVIEW
           TABLE 155 AENOVA GROUP: SERVICES OFFERED
             10.2.4 ALMAC GROUP
             10.2.5 CAMBREX
             10.2.6 CORDENPHARMA
             10.2.7 BIOVECTRA
             10.2.8 ALBANY MOLECULAR RESEARCH
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies. 

11 APPENDIX (Page No. - 189)
     11.1 DISCUSSION GUIDE
     11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.3 AVAILABLE CUSTOMIZATIONS
     11.4 RELATED REPORTS
     11.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the pharmaceutical contract development and manufacturing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract development and manufacturing market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include publications from government sources (such as the Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organisation (CDSCO), Indian Brand Equity Foundation (IBEF), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), PharmaTimes, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), World Journal of Pharmaceutical Sciences. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Pharmaceutical Contract Development and Manufacturing Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the pharmaceutical contract development and manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the pharmaceutical contract development and manufacturing business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the pharmaceutical contract development and manufacturing market based on service, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities and trends)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall pharmaceutical contract development and manufacturing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the pharmaceutical contract development and manufacturing market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

An additional five company profiles

COVID-19

Get in-depth analysis of the COVID-19 impact on the Pharmaceutical Contract Development and Manufacturing Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Pharmaceutical Contract Development and Manufacturing Market

Request For Special Pricing
Report Code
PH 7263
Published ON
Mar, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Development and Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home